MXPA05009193A - Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. - Google Patents
Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.Info
- Publication number
- MXPA05009193A MXPA05009193A MXPA05009193A MXPA05009193A MXPA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A
- Authority
- MX
- Mexico
- Prior art keywords
- obesity
- biaryltetrahydroisoquinoline
- piperidines
- treatment
- receptor antagonists
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 title 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 abstract 3
- 102000047659 melanin-concentrating hormone Human genes 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente invencion describe compuestos que son novedosos antagonistas para la hormona concentradora de melanina (MCH), asi como tambien los metodos para preparar dichos compuestos; en otros aspectos, la invencion esta dirigida a composiciones farmaceuticas que comprenden dichos antagonistas de la MCH asi como tambien los metodos para utilizarlos para tratar la obesidad, los trastornos metabolicos, los trastornos de la alimentacion, tales como hiperfagia, y diabetes; los compuestos de la invencion tienen en general la estructura; (ver formula) en la cual los sustituyentes son tal como se han definido en la presente descripcion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45079903P | 2003-02-28 | 2003-02-28 | |
PCT/US2004/005780 WO2004078745A1 (en) | 2003-02-28 | 2004-02-26 | Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05009193A true MXPA05009193A (es) | 2005-10-18 |
Family
ID=32962533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05009193A MXPA05009193A (es) | 2003-02-28 | 2004-02-26 | Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. |
Country Status (12)
Country | Link |
---|---|
US (1) | US7498441B2 (es) |
EP (1) | EP1601664B1 (es) |
JP (1) | JP4570165B2 (es) |
CN (1) | CN1777596A (es) |
AR (1) | AR043420A1 (es) |
AT (1) | ATE393766T1 (es) |
CA (1) | CA2517088A1 (es) |
DE (1) | DE602004013427T2 (es) |
ES (1) | ES2305735T3 (es) |
MX (1) | MXPA05009193A (es) |
TW (1) | TW200427679A (es) |
WO (1) | WO2004078745A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2121613A2 (en) | 2007-01-31 | 2009-11-25 | Vertex Pharmaceuticals, Inc. | 2-aminopyridine derivatives useful as kinase inhibitors |
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
JP5631310B2 (ja) | 2008-07-23 | 2014-11-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 三環式ピラゾロピリジンキナーゼ阻害剤 |
JP2011529062A (ja) | 2008-07-23 | 2011-12-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリジンキナーゼ阻害剤 |
JP2011530527A (ja) | 2008-08-06 | 2011-12-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | アミノピリジンキナーゼ阻害剤 |
MX2011011653A (es) | 2009-05-06 | 2012-01-20 | Vertex Pharma | Pirazolopiridinas. |
EP2528917B1 (en) | 2010-01-27 | 2016-10-19 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases |
AU2011209649A1 (en) | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
AU2011209651A1 (en) | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
US10398689B2 (en) * | 2015-12-22 | 2019-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
CN1157392C (zh) * | 1997-05-30 | 2004-07-14 | 神经研究公司 | 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物 |
EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
JP2004504303A (ja) * | 2000-07-05 | 2004-02-12 | シナプティック・ファーマスーティカル・コーポレーション | 選択的メラニン凝集ホルモン−1(mch1)受容体アンタゴニストおよびその使用 |
EP1377293B1 (en) | 2001-04-12 | 2010-03-10 | Pharmacopeia, LLC | Aryl and biaryl piperidines used as mch antagonists |
EP1532147B1 (en) * | 2002-06-27 | 2006-08-02 | Schering Corporation | Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
-
2004
- 2004-02-26 CA CA002517088A patent/CA2517088A1/en not_active Abandoned
- 2004-02-26 DE DE602004013427T patent/DE602004013427T2/de not_active Expired - Lifetime
- 2004-02-26 AT AT04715072T patent/ATE393766T1/de not_active IP Right Cessation
- 2004-02-26 MX MXPA05009193A patent/MXPA05009193A/es active IP Right Grant
- 2004-02-26 JP JP2006508855A patent/JP4570165B2/ja not_active Expired - Fee Related
- 2004-02-26 TW TW093104942A patent/TW200427679A/zh unknown
- 2004-02-26 WO PCT/US2004/005780 patent/WO2004078745A1/en active Application Filing
- 2004-02-26 US US10/788,109 patent/US7498441B2/en not_active Expired - Fee Related
- 2004-02-26 CN CNA2004800109047A patent/CN1777596A/zh active Pending
- 2004-02-26 EP EP04715072A patent/EP1601664B1/en not_active Expired - Lifetime
- 2004-02-26 ES ES04715072T patent/ES2305735T3/es not_active Expired - Lifetime
- 2004-02-27 AR ARP040100622A patent/AR043420A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ES2305735T3 (es) | 2008-11-01 |
CN1777596A (zh) | 2006-05-24 |
EP1601664A1 (en) | 2005-12-07 |
DE602004013427T2 (de) | 2009-06-04 |
AR043420A1 (es) | 2005-07-27 |
TW200427679A (en) | 2004-12-16 |
WO2004078745A1 (en) | 2004-09-16 |
JP2006520399A (ja) | 2006-09-07 |
EP1601664B1 (en) | 2008-04-30 |
DE602004013427D1 (de) | 2008-06-12 |
US7498441B2 (en) | 2009-03-03 |
JP4570165B2 (ja) | 2010-10-27 |
CA2517088A1 (en) | 2004-09-16 |
US20040176355A1 (en) | 2004-09-09 |
ATE393766T1 (de) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04003858A (es) | Antagonistas de mch para el tratamiento de obesidad. | |
MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
MXPA04000707A (es) | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. | |
WO2006044293A3 (en) | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | |
EE200300415A (et) | Atsüülitud piperidiini derivaadid kui melanokortiin-4 retseptori agonistid ja farmatseutiline kompositsioon | |
NO20050749L (no) | Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene | |
TW200531689A (en) | Therapeutic agents | |
PL1735278T3 (pl) | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne | |
EP1773330A4 (en) | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | |
MY146972A (en) | Novel compounds as opioid receptor modulators. | |
ATE382353T1 (de) | Substiuierte piperidine als melanocortinrezeptor- modulatoren | |
EP1590336A4 (en) | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | |
IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
WO2004005262A3 (en) | New neuropeptide y y5 receptor antagonists | |
MXPA06003363A (es) | Derivados de fenil-piperazina como moduladores de receptores muscarinicos. | |
EA201070725A1 (ru) | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона | |
MXPA05009193A (es) | Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. | |
MXPA05013596A (es) | Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad. | |
ATE432702T1 (de) | Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
MXPA05012572A (es) | Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central. | |
HK1100176A1 (en) | Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | |
MY143477A (en) | Il-8 receptor antagonists | |
WO2005063697A3 (en) | Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders | |
AU2003262926A1 (en) | Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |